TP53 and colorectal carcinoma: Anti‐p53 antibodies, the most extensively researched autoantibodies in CRC, may serve as biomarkers to distinguish CRC from healthy individuals or benign patients, a potential supported by a summary receiver operating characteristic curve with an AUC of 0.78 (95% CI: 0.76–0.81) [16].